Annual CFI
$374.65 M
+$633.30 M+244.84%
31 December 2023
Summary:
CRISPR Therapeutics AG annual cash flow from investing activities is currently $374.65 million, with the most recent change of +$633.30 million (+244.84%) on 31 December 2023. During the last 3 years, it has risen by +$915.82 million (+169.23%). CRSP annual CFI is now at all-time high.CRSP Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$161.60 M
-$34.70 M-27.34%
30 September 2024
Summary:
CRISPR Therapeutics AG quarterly cash flow from investing activities is currently -$161.60 million, with the most recent change of -$34.70 million (-27.34%) on 30 September 2024. Over the past year, it has dropped by -$282.95 million (-233.17%). CRSP quarterly CFI is now -174.50% below its all-time high of $216.92 million, reached on 30 June 2023.CRSP Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$467.76 M
-$282.95 M-153.10%
30 September 2024
Summary:
CRISPR Therapeutics AG TTM cash flow from investing activities is currently -$467.76 million, with the most recent change of -$282.95 million (-153.10%) on 30 September 2024. Over the past year, it has dropped by -$748.33 million (-266.72%). CRSP TTM CFI is now -224.85% below its all-time high of $374.65 million, reached on 31 December 2023.CRSP TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRSP Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +244.8% | -233.2% | -266.7% |
| 3 y3 years | +169.2% | +71.4% | +62.0% |
| 5 y5 years | +10000.0% | -6466.6% | -6848.3% |
CRSP Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +136.2% | -174.5% | +71.4% | -224.8% | +62.0% |
| 5 y | 5 years | at high | +136.2% | -174.5% | +71.4% | -224.8% | +62.0% |
| alltime | all time | at high | +136.2% | -174.5% | +71.4% | -224.8% | +62.0% |
CRISPR Therapeutics AG Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$161.60 M(+27.3%) | -$467.76 M(+153.1%) |
| June 2024 | - | -$126.91 M(+29.8%) | -$184.81 M(-216.2%) |
| Mar 2024 | - | -$97.80 M(+20.1%) | $159.02 M(-57.6%) |
| Dec 2023 | $374.65 M(-244.8%) | -$81.45 M(-167.1%) | $374.65 M(+33.5%) |
| Sept 2023 | - | $121.35 M(-44.1%) | $280.57 M(+13.7%) |
| June 2023 | - | $216.92 M(+84.1%) | $246.68 M(-1037.6%) |
| Mar 2023 | - | $117.83 M(-167.1%) | -$26.31 M(-89.8%) |
| Dec 2022 | -$258.65 M(-75.0%) | -$175.53 M(-300.7%) | -$258.65 M(+181.6%) |
| Sept 2022 | - | $87.46 M(-256.0%) | -$91.84 M(-87.7%) |
| June 2022 | - | -$56.07 M(-51.0%) | -$744.48 M(-24.2%) |
| Mar 2022 | - | -$114.52 M(+1213.8%) | -$982.05 M(-5.2%) |
| Dec 2021 | -$1.04 B(+91.3%) | -$8.72 M(-98.5%) | -$1.04 B(-15.9%) |
| Sept 2021 | - | -$565.18 M(+92.5%) | -$1.23 B(+23.6%) |
| June 2021 | - | -$293.64 M(+74.9%) | -$996.11 M(+41.1%) |
| Mar 2021 | - | -$167.90 M(-17.8%) | -$706.08 M(+30.5%) |
| Dec 2020 | -$541.17 M | -$204.24 M(-38.2%) | -$541.17 M(+64.1%) |
| Sept 2020 | - | -$330.33 M(+9063.1%) | -$329.87 M(>+9900.0%) |
| June 2020 | - | -$3.60 M(+20.5%) | -$2.00 M(+251.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$2.99 M(-142.4%) | -$569.00 K(-142.9%) |
| Dec 2019 | $1.32 M(-147.8%) | $7.06 M(-386.8%) | $1.32 M(-119.7%) |
| Sept 2019 | - | -$2.46 M(+13.2%) | -$6.73 M(+35.6%) |
| June 2019 | - | -$2.17 M(+98.2%) | -$4.97 M(+49.8%) |
| Mar 2019 | - | -$1.10 M(+9.7%) | -$3.31 M(+19.5%) |
| Dec 2018 | -$2.77 M(-66.6%) | -$1.00 M(+43.9%) | -$2.77 M(+40.2%) |
| Sept 2018 | - | -$695.00 K(+32.9%) | -$1.98 M(-58.6%) |
| June 2018 | - | -$523.00 K(-5.8%) | -$4.78 M(-14.5%) |
| Mar 2018 | - | -$555.00 K(+170.7%) | -$5.58 M(-32.8%) |
| Dec 2017 | -$8.31 M(-126.1%) | -$205.00 K(-94.1%) | -$8.31 M(-224.8%) |
| Sept 2017 | - | -$3.49 M(+162.7%) | $6.66 M(-23.0%) |
| June 2017 | - | -$1.33 M(-59.5%) | $8.65 M(-3.2%) |
| Mar 2017 | - | -$3.29 M(-122.2%) | $8.93 M(-72.0%) |
| Dec 2016 | $31.88 M(-2862.9%) | $14.77 M(-1078.9%) | $31.88 M(+86.3%) |
| Sept 2016 | - | -$1.51 M(+44.1%) | $17.11 M(-8.1%) |
| June 2016 | - | -$1.05 M(-105.3%) | $18.62 M(-5.3%) |
| Mar 2016 | - | $19.67 M | $19.67 M |
| Dec 2015 | -$1.15 M(<-9900.0%) | - | - |
| Dec 2014 | $0.00 | - | - |
FAQ
- What is CRISPR Therapeutics AG annual cash flow from investing activities?
- What is the all time high annual CFI for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual CFI year-on-year change?
- What is CRISPR Therapeutics AG quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly CFI year-on-year change?
- What is CRISPR Therapeutics AG TTM cash flow from investing activities?
- What is the all time high TTM CFI for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG TTM CFI year-on-year change?
What is CRISPR Therapeutics AG annual cash flow from investing activities?
The current annual CFI of CRSP is $374.65 M
What is the all time high annual CFI for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual cash flow from investing activities is $374.65 M
What is CRISPR Therapeutics AG annual CFI year-on-year change?
Over the past year, CRSP annual cash flow from investing activities has changed by +$633.30 M (+244.84%)
What is CRISPR Therapeutics AG quarterly cash flow from investing activities?
The current quarterly CFI of CRSP is -$161.60 M
What is the all time high quarterly CFI for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly cash flow from investing activities is $216.92 M
What is CRISPR Therapeutics AG quarterly CFI year-on-year change?
Over the past year, CRSP quarterly cash flow from investing activities has changed by -$282.95 M (-233.17%)
What is CRISPR Therapeutics AG TTM cash flow from investing activities?
The current TTM CFI of CRSP is -$467.76 M
What is the all time high TTM CFI for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high TTM cash flow from investing activities is $374.65 M
What is CRISPR Therapeutics AG TTM CFI year-on-year change?
Over the past year, CRSP TTM cash flow from investing activities has changed by -$748.33 M (-266.72%)